{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T16:11:50Z","timestamp":1726071110085},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.phrs.2004.05.003","type":"journal-article","created":{"date-parts":[[2004,6,16]],"date-time":"2004-06-16T11:57:45Z","timestamp":1087387065000},"page":"517-522","source":"Crossref","is-referenced-by-count":7,"title":["Effects of sibutramine on anxiety-related behaviours in rats"],"prefix":"10.1016","volume":"50","author":[{"given":"Salim Dem\u00e9trio","family":"Jorge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger Lu\u0131\u0301s Henschel","family":"Pobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"de Paula Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"H\u00e9lio","family":"Zangrossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.phrs.2004.05.003_BIB1","first-page":"S18","article-title":"Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine","volume":"22","author":"Heal","year":"1998","journal-title":"Int. J. Obes. Relat. Metab. Disord"},{"key":"10.1016\/j.phrs.2004.05.003_BIB2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0278-5846(88)90003-6","article-title":"The pharmacology of sibutramine hydrochloride (BTS 54 524), a new anti-depressant which induces rapid noradrenergic down-regulation","volume":"12","author":"Buckett","year":"1988","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2004.05.003_BIB3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.1988.tb05303.x","article-title":"Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new anti-depressant, in healthy volunteers","volume":"26","author":"King","year":"1988","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1016\/j.phrs.2004.05.003_BIB4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02244604","article-title":"Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the anti-depressant sibutramine HCl","volume":"100","author":"Luscombe","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2004.05.003_BIB5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1345\/aph.18319","article-title":"Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity","volume":"33","author":"Luque","year":"1999","journal-title":"Ann. Pharmacother"},{"key":"10.1016\/j.phrs.2004.05.003_BIB6","first-page":"145","article-title":"Sibutramine weight loss in depressed patients","volume":"19","author":"Kelly","year":"1995","journal-title":"Int. J. Obes"},{"key":"10.1016\/j.phrs.2004.05.003_BIB7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-2999(02)01423-1","article-title":"The discovery and status of sibutramine as an anti-obesity drug","volume":"440","author":"Luque","year":"2002","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.phrs.2004.05.003_BIB8","first-page":"477","article-title":"Panic Disorder: Efficacy of current treatments","volume":"29","author":"Ballenger","year":"1993","journal-title":"Psychopharmacol. Bull"},{"key":"10.1016\/j.phrs.2004.05.003_BIB9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0163-7258(00)00083-8","article-title":"The psychobiology of anxiolytic drugs. Part 2: pharmacological treatments of anxiety","volume":"88","author":"Argyropoulos","year":"2000","journal-title":"Pharmacol. Ther"},{"key":"10.1016\/j.phrs.2004.05.003_BIB10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00008877-199711000-00003","article-title":"Animal models of \u2018anxiety\u2019: where next?","volume":"8","author":"Rodgers","year":"1997","journal-title":"Behav. Pharmacol"},{"key":"10.1016\/j.phrs.2004.05.003_BIB11","doi-asserted-by":"crossref","unstructured":"Graeff FG, Zangrossi H, Jr. Animal models of anxiety disorders. In: D\u2019haenen H, Den Boer JA, Westenberg H, Willner P., editors. Textbook of Biological Psychiatry. Chichester: Wiley; 2002. p. 879\u201393.","DOI":"10.1002\/0470854871.chxix1"},{"key":"10.1016\/j.phrs.2004.05.003_BIB12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0091-3057(99)00261-0","article-title":"Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety","volume":"65","author":"Teixeira","year":"2000","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.phrs.2004.05.003_BIB13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0166-4328(03)00151-7","article-title":"Anti-panic-like effect of serotonin reuptake inhibitors in the elevated T-maze","volume":"147","author":"Poltronieri","year":"2003","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.phrs.2004.05.003_BIB14","first-page":"67","article-title":"The elevated T-maze, a new experimental model of anxiety and memory: effect of diazepam","volume":"26","author":"Graeff","year":"1993","journal-title":"Braz. J. Med. Biol. Res"},{"key":"10.1016\/j.phrs.2004.05.003_BIB15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0149-7634(98)00024-4","article-title":"The elevated T-maze as an experimental model of anxiety","volume":"23","author":"Graeff","year":"1998","journal-title":"Neurosci. Biobehav. Rev"},{"key":"10.1016\/j.phrs.2004.05.003_BIB16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0091-3057(94)90067-1","article-title":"The elevated T-maze: a new animal model of anxiety and memory","volume":"49","author":"Viana","year":"1994","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.phrs.2004.05.003_BIB17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/1043-6618(89)90201-6","article-title":"A two-compartment exploratory model to study anxiolytic\/anxiogenic effects of drugs in the rat","volume":"21","author":"Pich","year":"1989","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2004.05.003_BIB18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0166-4328(96)00160-X","article-title":"Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light\/dark and dark\/light tests","volume":"85","author":"Chaouloff","year":"1997","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.phrs.2004.05.003_BIB19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002130050568","article-title":"mCPP-induced anxiety in the light-dark box in rats\u2014a new method for screening anxiolytic activity","volume":"136","author":"Bilkei-Gorzo","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2004.05.003_BIB20","unstructured":"Rodgers RJ, Cole JC. The elevate plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA, editors. Ethology and Psychopharmacology. Chichester: John Wiley and Sons; 1994. p. 9\u201343."},{"key":"10.1016\/j.phrs.2004.05.003_BIB21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(95)98597-J","article-title":"5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research","volume":"65","author":"Griebel","year":"1995","journal-title":"Pharmacol. Ther"},{"key":"10.1016\/j.phrs.2004.05.003_BIB22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/026988119100500417","article-title":"5-HT\u2014the disengaging transmitter?","volume":"5","author":"Handley","year":"1991","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.phrs.2004.05.003_BIB23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0166-4328(93)90104-X","article-title":"Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors","volume":"58","author":"Handley","year":"1993","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.phrs.2004.05.003_BIB24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/026988119100500414","article-title":"5-HT and mechanisms of defense","volume":"5","author":"Deakin","year":"1991","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.phrs.2004.05.003_BIB25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0091-3057(95)02135-3","article-title":"Role of 5-HT in stress, anxiety, and depression","volume":"54","author":"Graeff","year":"1996","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.phrs.2004.05.003_BIB26","unstructured":"Gray JA, McNaughton N. The neuropsychology of anxiety. Oxford: Oxford University Press, 2000."},{"key":"10.1016\/j.phrs.2004.05.003_BIB27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00213-002-1112-4","article-title":"On serotonin and experimental anxiety","volume":"163","author":"Graeff","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2004.05.003_BIB28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0091-3057(88)90089-5","article-title":"Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release","volume":"30","author":"Fuller","year":"1988","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.phrs.2004.05.003_BIB29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s002139900342","article-title":"d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine","volume":"149","author":"Mortimore","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2004.05.003_BIB30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/BF02806003","article-title":"Effect of d-fenfluramine on human experimental anxiety","volume":"127","author":"Hetem","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2004.05.003_BIB31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/ajp.151.4.621b","article-title":"Controlling panic attacks with fenfluramine","volume":"151","author":"Solyom","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2004.05.003_BIB32","first-page":"80","article-title":"Anorexigen-related cardiopulmonary toxicity","volume":"1","author":"Gross","year":"2000","journal-title":"Rev. Cardiovasc. Med"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661804001100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661804001100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T02:56:13Z","timestamp":1549508173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661804001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S1043661804001100"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2004.05.003","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}